vs
Side-by-side financial comparison of HANMI FINANCIAL CORP (HAFC) and Phathom Pharmaceuticals, Inc. (PHAT). Click either name above to swap in a different company.
HANMI FINANCIAL CORP is the larger business by last-quarter revenue ($71.2M vs $57.6M, roughly 1.2× Phathom Pharmaceuticals, Inc.). On growth, Phathom Pharmaceuticals, Inc. posted the faster year-over-year revenue change (94.1% vs 17.1%). HANMI FINANCIAL CORP produced more free cash flow last quarter ($203.7M vs $-167.0M).
Hanmi Bank Corporation is a community bank headquartered in Los Angeles, California, with 35 branches and eight loan production offices in California, Texas, Illinois, New York, New Jersey and Virginia.
Phathom Pharmaceuticals is a clinical-stage biopharmaceutical firm focused on developing and commercializing innovative therapies for gastrointestinal diseases. Its lead product candidates address acid-related disorders, inflammatory bowel disease, and other GI conditions, serving patients mainly across North America and Europe.
HAFC vs PHAT — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $71.2M | $57.6M |
| Net Profit | $21.2M | — |
| Gross Margin | — | 86.7% |
| Operating Margin | 29.8% | — |
| Net Margin | 29.8% | — |
| Revenue YoY | 17.1% | 94.1% |
| Net Profit YoY | 20.0% | 71.6% |
| EPS (diluted) | $0.70 | — |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $71.2M | $57.6M | ||
| Q3 25 | $71.0M | $49.5M | ||
| Q2 25 | $65.2M | $39.5M | ||
| Q1 25 | $62.8M | $28.5M | ||
| Q4 24 | $60.8M | $29.7M | ||
| Q3 24 | $58.5M | $16.4M | ||
| Q2 24 | $56.7M | $7.3M | ||
| Q1 24 | $58.4M | — |
| Q4 25 | $21.2M | — | ||
| Q3 25 | $22.1M | $-30.0M | ||
| Q2 25 | $15.1M | $-75.8M | ||
| Q1 25 | $17.7M | $-94.3M | ||
| Q4 24 | $17.7M | — | ||
| Q3 24 | $14.9M | $-85.6M | ||
| Q2 24 | $14.5M | $-91.4M | ||
| Q1 24 | $15.2M | — |
| Q4 25 | — | 86.7% | ||
| Q3 25 | — | 87.5% | ||
| Q2 25 | — | 87.2% | ||
| Q1 25 | — | 86.9% | ||
| Q4 24 | — | 87.1% | ||
| Q3 24 | — | 85.6% | ||
| Q2 24 | — | 81.2% | ||
| Q1 24 | — | — |
| Q4 25 | 29.8% | — | ||
| Q3 25 | 31.1% | -30.8% | ||
| Q2 25 | 23.2% | -151.7% | ||
| Q1 25 | 28.1% | -276.5% | ||
| Q4 24 | 29.1% | — | ||
| Q3 24 | 25.5% | -433.0% | ||
| Q2 24 | 25.5% | -1055.4% | ||
| Q1 24 | 26.0% | — |
| Q4 25 | 29.8% | — | ||
| Q3 25 | 31.1% | -60.5% | ||
| Q2 25 | 23.2% | -191.9% | ||
| Q1 25 | 28.1% | -330.7% | ||
| Q4 24 | 29.1% | — | ||
| Q3 24 | 25.5% | -523.3% | ||
| Q2 24 | 25.5% | -1248.6% | ||
| Q1 24 | 26.0% | — |
| Q4 25 | $0.70 | — | ||
| Q3 25 | $0.73 | $-0.41 | ||
| Q2 25 | $0.50 | $-1.05 | ||
| Q1 25 | $0.58 | $-1.31 | ||
| Q4 24 | $0.58 | — | ||
| Q3 24 | $0.49 | $-1.32 | ||
| Q2 24 | $0.48 | $-1.56 | ||
| Q1 24 | $0.50 | — |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | — | $130.0M |
| Total DebtLower is stronger | — | $209.1M |
| Stockholders' EquityBook value | $796.4M | $-438.2M |
| Total Assets | $7.9B | $259.1M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $130.0M | ||
| Q3 25 | — | $135.2M | ||
| Q2 25 | — | $149.6M | ||
| Q1 25 | — | $212.3M | ||
| Q4 24 | — | $297.3M | ||
| Q3 24 | — | $334.7M | ||
| Q2 24 | — | $276.2M | ||
| Q1 24 | — | — |
| Q4 25 | — | $209.1M | ||
| Q3 25 | — | $207.1M | ||
| Q2 25 | — | $205.1M | ||
| Q1 25 | — | $203.2M | ||
| Q4 24 | — | $201.4M | ||
| Q3 24 | — | $175.7M | ||
| Q2 24 | — | $174.4M | ||
| Q1 24 | — | — |
| Q4 25 | $796.4M | $-438.2M | ||
| Q3 25 | $779.5M | $-422.5M | ||
| Q2 25 | $762.8M | $-405.8M | ||
| Q1 25 | $751.5M | $-338.4M | ||
| Q4 24 | $732.2M | $-253.6M | ||
| Q3 24 | $736.7M | $-187.1M | ||
| Q2 24 | $707.1M | $-233.8M | ||
| Q1 24 | $703.1M | — |
| Q4 25 | $7.9B | $259.1M | ||
| Q3 25 | $7.9B | $240.3M | ||
| Q2 25 | $7.9B | $250.2M | ||
| Q1 25 | $7.7B | $294.2M | ||
| Q4 24 | $7.7B | $378.3M | ||
| Q3 24 | $7.7B | $387.0M | ||
| Q2 24 | $7.6B | $319.4M | ||
| Q1 24 | $7.5B | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $206.0M | $-166.8M |
| Free Cash FlowOCF − Capex | $203.7M | $-167.0M |
| FCF MarginFCF / Revenue | 286.2% | -290.0% |
| Capex IntensityCapex / Revenue | 3.2% | 0.4% |
| Cash ConversionOCF / Net Profit | 9.70× | — |
| TTM Free Cash FlowTrailing 4 quarters | $356.1M | $-328.9M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $206.0M | $-166.8M | ||
| Q3 25 | $146.9M | $-14.1M | ||
| Q2 25 | $-19.0M | $-62.7M | ||
| Q1 25 | $25.8M | $-84.9M | ||
| Q4 24 | $52.6M | $-266.8M | ||
| Q3 24 | $6.7M | $-63.6M | ||
| Q2 24 | $2.1M | $-70.7M | ||
| Q1 24 | $30.0M | — |
| Q4 25 | $203.7M | $-167.0M | ||
| Q3 25 | $146.4M | $-14.1M | ||
| Q2 25 | $-19.6M | $-62.8M | ||
| Q1 25 | $25.6M | $-84.9M | ||
| Q4 24 | $49.9M | $-266.9M | ||
| Q3 24 | $6.5M | $-63.6M | ||
| Q2 24 | $1.3M | $-70.8M | ||
| Q1 24 | $29.2M | — |
| Q4 25 | 286.2% | -290.0% | ||
| Q3 25 | 206.3% | -28.6% | ||
| Q2 25 | -30.0% | -159.0% | ||
| Q1 25 | 40.7% | -297.9% | ||
| Q4 24 | 82.1% | -899.8% | ||
| Q3 24 | 11.1% | -389.0% | ||
| Q2 24 | 2.3% | -966.2% | ||
| Q1 24 | 50.0% | — |
| Q4 25 | 3.2% | 0.4% | ||
| Q3 25 | 0.8% | 0.1% | ||
| Q2 25 | 0.9% | 0.2% | ||
| Q1 25 | 0.4% | 0.1% | ||
| Q4 24 | 4.3% | 0.5% | ||
| Q3 24 | 0.4% | 0.3% | ||
| Q2 24 | 1.4% | 0.6% | ||
| Q1 24 | 1.4% | — |
| Q4 25 | 9.70× | — | ||
| Q3 25 | 6.66× | — | ||
| Q2 25 | -1.26× | — | ||
| Q1 25 | 1.46× | — | ||
| Q4 24 | 2.97× | — | ||
| Q3 24 | 0.45× | — | ||
| Q2 24 | 0.14× | — | ||
| Q1 24 | 1.98× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
